294 related articles for article (PubMed ID: 37335163)
1. What nature has to offer: Opportunities for immuno-oncology.
Kousar R; Lin CH; Patrick B; He M; Wu DC; Li XG
J Food Drug Anal; 2023 Jun; 31(2):212-231. PubMed ID: 37335163
[TBL] [Abstract][Full Text] [Related]
2. Cancer Epigenetics, Tumor Immunity, and Immunotherapy.
Cao J; Yan Q
Trends Cancer; 2020 Jul; 6(7):580-592. PubMed ID: 32610068
[TBL] [Abstract][Full Text] [Related]
3. Epigenetic remodeling of the immune landscape in cancer: therapeutic hurdles and opportunities.
Tien FM; Lu HH; Lin SY; Tsai HC
J Biomed Sci; 2023 Jan; 30(1):3. PubMed ID: 36627707
[TBL] [Abstract][Full Text] [Related]
4. The emerging role of epigenetic therapeutics in immuno-oncology.
Topper MJ; Vaz M; Marrone KA; Brahmer JR; Baylin SB
Nat Rev Clin Oncol; 2020 Feb; 17(2):75-90. PubMed ID: 31548600
[TBL] [Abstract][Full Text] [Related]
5. H3K4 trimethylation regulates cancer immunity: a promising therapeutic target in combination with immunotherapy.
Xiao C; Fan T; Zheng Y; Tian H; Deng Z; Liu J; Li C; He J
J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37553181
[TBL] [Abstract][Full Text] [Related]
6. Epigenetic Perspective of Immunotherapy for Cancers.
Keshari S; Barrodia P; Singh AK
Cells; 2023 Jan; 12(3):. PubMed ID: 36766706
[TBL] [Abstract][Full Text] [Related]
7. The interaction between DNA methylation and tumor immune microenvironment: from the laboratory to clinical applications.
Zhu D; Zeng S; Su C; Li J; Xuan Y; Lin Y; Xu E; Fan Q
Clin Epigenetics; 2024 Feb; 16(1):24. PubMed ID: 38331927
[TBL] [Abstract][Full Text] [Related]
8. Epigenetics and immunotherapy: The current state of play.
Dunn J; Rao S
Mol Immunol; 2017 Jul; 87():227-239. PubMed ID: 28511092
[TBL] [Abstract][Full Text] [Related]
9. Leveraging NKG2D Ligands in Immuno-Oncology.
Fuertes MB; Domaica CI; Zwirner NW
Front Immunol; 2021; 12():713158. PubMed ID: 34394116
[TBL] [Abstract][Full Text] [Related]
10. Epigenetic regulation in the tumor microenvironment: molecular mechanisms and therapeutic targets.
Yang J; Xu J; Wang W; Zhang B; Yu X; Shi S
Signal Transduct Target Ther; 2023 May; 8(1):210. PubMed ID: 37217462
[TBL] [Abstract][Full Text] [Related]
11. Emerging Epigenetic-Based Nanotechnology for Cancer Therapy: Modulating the Tumor Microenvironment.
Zhang J; Huang L; Ge G; Hu K
Adv Sci (Weinh); 2023 Mar; 10(7):e2206169. PubMed ID: 36599655
[TBL] [Abstract][Full Text] [Related]
12. The Cancer Epigenome: Exploiting Its Vulnerabilities for Immunotherapy.
Loo Yau H; Ettayebi I; De Carvalho DD
Trends Cell Biol; 2019 Jan; 29(1):31-43. PubMed ID: 30153961
[TBL] [Abstract][Full Text] [Related]
13. Reshaping immunometabolism in the tumour microenvironment to improve cancer immunotherapy.
Chen S; Duan H; Sun G
Biomed Pharmacother; 2023 Aug; 164():114963. PubMed ID: 37269814
[TBL] [Abstract][Full Text] [Related]
14. Is there a Role for Epigenetic Enhancement of Immunomodulatory Approaches to Cancer Treatment?
Flower KJ; Ghaem-Maghami S; Brown R
Curr Cancer Drug Targets; 2018; 18(1):5-15. PubMed ID: 28176650
[TBL] [Abstract][Full Text] [Related]
15. Lysine-Specific Demethylase 1 (LSD1)-Mediated Epigenetic Modification of Immunogenicity and Immunomodulatory Effects in Breast Cancers.
Lee DY; Salahuddin T; Iqbal J
Curr Oncol; 2023 Feb; 30(2):2127-2143. PubMed ID: 36826125
[TBL] [Abstract][Full Text] [Related]
16. Targeting ARID1A-Deficient Cancers: An Immune-Metabolic Perspective.
Lebedev T; Kousar R; Patrick B; Usama M; Lee MK; Tan M; Li XG
Cells; 2023 Mar; 12(6):. PubMed ID: 36980292
[TBL] [Abstract][Full Text] [Related]
17. The Contribution of Epigenetics to Cancer Immunotherapy.
Villanueva L; Álvarez-Errico D; Esteller M
Trends Immunol; 2020 Aug; 41(8):676-691. PubMed ID: 32622854
[TBL] [Abstract][Full Text] [Related]
18. Targeting the epigenetic processes to enhance antitumor immunity in small cell lung cancer.
Luo H; Shan J; Zhang H; Song G; Li Q; Xu CX
Semin Cancer Biol; 2022 Nov; 86(Pt 3):960-970. PubMed ID: 35189321
[TBL] [Abstract][Full Text] [Related]
19. Anticancer potential of naturally occurring immunoepigenetic modulators: A promising avenue?
Schnekenburger M; Dicato M; Diederich MF
Cancer; 2019 May; 125(10):1612-1628. PubMed ID: 30840315
[TBL] [Abstract][Full Text] [Related]
20. Targeting the tumor microenvironment: removing obstruction to anticancer immune responses and immunotherapy.
Pitt JM; Marabelle A; Eggermont A; Soria JC; Kroemer G; Zitvogel L
Ann Oncol; 2016 Aug; 27(8):1482-92. PubMed ID: 27069014
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
